

GridAI Technologies Corp. (GRDX)

Nasdaq; utilities; SIC 4931, Electric & Other Services Combined; CIK 0001604191

GridAI Technologies Corp. GRDX; utilities		
Grade	None 6 of 14 inputs computable; 7 are required	Share price, twelve months to the rescan split-adjusted close; the letter is fixed at the rescan that set it 
Reliability	0.83 AUC filers with \$12.5M to \$120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025	
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025	
Size band	\$12.5M to \$120M assets total assets \$48.6M	
Standard universe	outside revenue above \$1M and assets above \$10M	
Warnings	dilution, short runway, late filer, thin data, degenerate inputs not computable: distress, fortress balance sheet	
Inputs computable	6 of 14	
Graded from	filings received through May 1, 2026 161 days before the rescan; latest periodic filing 10-Q received Aug 21, 2026	
Last close	\$4.80 2026-10-08; market equity \$34.2M	
Price used in grade	None	

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only

A	
B	
C	
D	
E	
	20132014201520162017201820192020202120222023202420252026

Business, in the company's words

opening of Item 1 of the 10-K received May 1, 2026

GridAI Technologies Corp., formerly known as Entero Therapeutics, Inc., is a diversified technology and life sciences company operating through two principal areas: (i) energy orchestration and grid optimization software solutions through our subsidiary Grid AI Corp. and (ii) legacy biopharmaceutical development activities centered on Adrulipase for the treatment of exocrine pancreatic insufficiency. Effective December 1, 2025, the Company changed its name from "Entero Therapeutics, Inc." to "GridAI Technologies Corp." and changed its Nasdaq trading symbol from "ENTO" to "GRDX".

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 93.2						
Gross profitability		(1.4%)	17.5%	95.0	81	2025-12-31
Return on invested capital		not computable	6.0%			one or more required annual facts are missing

Accruals ratio		(1.0%)	(5.0%)	91.5	271	2025-12-31
Gross margin stability, five years		not computable	4.6 pts			five annual gross margins are required; found 1
Solvency, sleeve percentile 95.9						
Twelve-month failure probability		not computable	0.06%			latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-prime		(15.37)	1.48	94.7	152	2025-12-31
Net debt to EBITDA		not computable	3.63x			one or more required annual facts are missing interest expense must exceed \$100,000
Interest coverage		not computable	2.37x			
Current ratio		0.17x	0.97x	97.2	282	2025-12-31
Growth and financing, sleeve percentile 50.8						
Revenue growth, three-year compound		not computable	0.7%			four annual observations are required; found 2
Free cash flow growth, three-year compound		not computable	(11.8%)			current FCF must be positive and base FCF must exceed \$100,000
Reinvestment rate		not computable	59.0%			NOPAT must exceed \$100,000
Asset growth, three years		107.4%	6.4%	1.6	246	2025-12-31
Net share issuance, one year		290.2%	0.4%	100.0	157	2026-05-01

Warnings

5 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 290.2%
Short runway	cash runway is 2.0 months
Late filer	found 5 NT 10-K/Q filings in the last eight quarters
Thin data	6 of 14 grade factors are computable; minimum is 7
Degenerate inputs	latest revenue or assets are at or below the \$100,000 validity floor

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(25.6%)	15.5%	6
Distance from 52-week high	(29.4%)	(15.4%)	18
EBIT to enterprise value	not computable	4.6%	
Free cash flow yield	(94.5%)	1.3%	3

Book value to price	0.43	0.53	30
Sales to price	0.00	0.45	0
Composite equity issuance, five years	not computable	(7.2%)	
Relative strength against the sector, log excess return	(0.28)	0.04	15

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	\$1.4M
Operating cash flow, four quarters	-\$8.1M
Months of runway	2.0
Days since last periodic filing	49 (10-Q received Aug 21, 2026)
Median daily dollar volume, 63 sessions	\$283,739

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	-\$657,432	2025-12-31	2026-05-01	10-K	0001104659-26-054106
2	assets	us-gaap:Assets	\$48.6M	2025-12-31	2026-05-01	10-K	0001104659-26-054106
3	net income	us-gaap:NetIncomeLoss	-\$6.4M	2025-12-31	2026-05-01	10-K	0001104659-26-054106
4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$5.7M	2025-12-31	2026-05-01	10-K	0001104659-26-054106
5	assets	us-gaap:Assets	\$85.4M	2024-12-31	2026-05-01	10-K	0001104659-26-054106
6	current assets	us-gaap:AssetsCurrent	\$2.6M	2025-12-31	2026-05-01	10-K	0001104659-26-054106
7	current liabilities	us-gaap:LiabilitiesCurrent	\$15.2M	2025-12-31	2026-05-01	10-K	0001104659-26-054106
8	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$208.8M	2025-12-31	2026-05-01	10-K	0001104659-26-054106
9	operating income	us-gaap:OperatingIncomeLoss	-\$7.1M	2025-12-31	2026-05-01	10-K	0001104659-26-054106
10	book equity	us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrolling	\$14.9M	2025-12-31	2026-05-01	10-K	0001104659-26-054106
11	liabilities	us-gaap:Liabilities	\$19.7M	2025-12-31	2026-05-01	10-K	0001104659-26-054106
12	operating income	us-gaap:OperatingIncomeLoss	-\$15.8M	2023-12-31	2025-04-09	10-K/A	0001410578-25-000673
13	interest expense	us-gaap:InterestExpense	\$22,463	2023-12-31	2024-03-29	10-K	0001410578-24-000364
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$36,251	2025-12-31	2026-05-01	10-K	0001104659-26-054106
15	revenue	us-gaap:Revenues	\$0	2019-12-31	2020-03-30	10-K	0001654954-20-003530
16	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$32.3M	2021-12-31	2023-03-20	10-K	0001410578-23-000299
17	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$69,488	2021-12-31	2023-03-20	10-K	0001410578-23-000299
18	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$11.2M	2020-12-31	2022-03-31	10-K	0001140361-22-012347
19	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$4,167	2020-12-31	2022-03-31	10-K	0001140361-22-012347
20	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$14.0M	2019-12-31	2021-03-31	10-K	0001654954-21-003659
21	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$24,098	2019-12-31	2021-03-31	10-K	0001654954-21-003659
22	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$10.9M	2018-12-31	2020-03-30	10-K	0001654954-20-003530
23	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$55,473	2018-12-31	2020-03-30	10-K	0001654954-20-003530
24	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$38,000	2020-12-31	2022-03-31	10-K	0001140361-22-012347
25	operating income	us-gaap:OperatingIncomeLoss	-\$26.4M	2020-12-31	2022-03-31	10-K	0001140361-22-012347
26	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraord	\$32.7M	2020-12-31	2021-03-31	10-K	0001654954-21-003659
27	income tax	us-gaap:IncomeTaxExpenseBenefit	\$0	2020-12-31	2022-03-31	10-K	0001140361-22-012347
28	current assets	us-gaap:AssetsCurrent	\$7.9M	2020-12-31	2022-03-31	10-K	0001140361-22-012347
29	current liabilities	us-gaap:LiabilitiesCurrent	\$15.5M	2020-12-31	2022-03-31	10-K	0001140361-22-012347
30	current assets	us-gaap:AssetsCurrent	\$3.4M	2019-12-31	2021-03-31	10-K	0001654954-21-003659
31	current liabilities	us-gaap:LiabilitiesCurrent	\$4.3M	2019-12-31	2021-03-31	10-K	0001654954-21-003659

32	assets	us-gaap:Assets	\$6.9M	2023-12-31	2025-04-09	10-K/A	0001410578-25-000673
33	assets	us-gaap:Assets	\$5.4M	2022-12-31	2024-03-29	10-K	0001410578-24-000364
34	shares outstanding	dei:EntityCommonStockSharesOutstanding	6,200,051	2026-05-01	2026-05-01	10-K	0001104659-26-054106
35	shares outstanding	dei:EntityCommonStockSharesOutstanding	4,765,729	2025-04-01	2025-04-09	10-K/A	0001410578-25-000673